WGU D027 Practice Test #2 Questions and Answers 100% Correct

WGU D027 Practice Test #2 Questions and Answers 100% CorrectWGU D027 Practice Test #2 Questions and Answers 100% CorrectWGU D027 Practice Test #2 Questions and Answers 100% CorrectWGU D027 Practice Test #2 Questions and Answers 100% CorrectAs an advanced practice nurse, you want to learn more about the CDC's initiatives relative to asthma care and management in order to advocate for asthma sufferers at the state legislative level. Your goal is to reduce medications costs to patients. Which CDC recommendation supports your goal? a. The CDC recommends that payers and employers promote healthy workspaces to decrease environmental trigger exposures. b. The CDC recommends that providers prescribe the most cost-efficient long-acting inhalers to lower patient co-pays. c. The CDC recommends that providers deviate from the stepwise approach to lessen the financial impact to the patient. d. The CDC recommends that co-pays be removed for inhaled corticosteroids and other prescribed medications - ANSWER-d. The CDC recommends that co-pays be removed for inhaled corticosteroids and other prescribed medications What syndrome, characterized by an absent homologous X chromosome with only a single X chromosome, exhibits features that include a short stature, total chromosome count of 45, webbed neck, and a shield like chest? a. Cri du chat syndrome b. Down syndrome c. Klinefelter syndrome d. Turner syndrome - ANSWER-d. Turner syndrome A female patient has been recently diagnosed with invasive ductal carcinoma. As an advanced practice nurse, you understand that she will be undergoing a multi-faceted treatment approach that will include one or more medications. Which medication is considered the "gold standard" endocrine treatment for breast cancer? a. Fulvestrant (Faslodex), an antiestrogen indicated for metastatic estrogen receptor-positive breast cancer in post-menopausal women b. Tamoxifen (Nolvadex), a prodrug that must be converted to active metabolites in order to block estrogen receptors in breast tissue c. Trastuzumab (Herceptin), a monoclonal antibody approved for HER2-positive metastatic breast cancer d. Lapatinib (Tykerb), an oral inhibitor of HER2 tyrosine kinase and EGFR tyrosine kinase, resulting in apoptosis and suppression of tumor cell growth - ANSWER-b. Tamoxifen (Nolvadex), a prodrug that must be converted to active metabolites in order to block estrogen receptors in breast tissue